China Biologic Products Holding (NASDAQ:CBPO)

Tuesday, September 24, 2019 | Web News
BEIJING, Sept. 24, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or...
Monday, May 13, 2019 | Web News
First Quarter 2019 Financial Results Total sales in the first quarter of 2019 increased by 22.3% in RMB terms and 15.4% in USD...
Thursday, March 7, 2019 | Web News
Fourth Quarter 2018 Financial Results Total sales in the fourth quarter of 2018 increased by 33.5% in RMB terms and 27.5% in USD...
See All Research...

At least one FIE exists in the corporate structure

China Biologic Products, Inc., through its indirect majority-owned subsidiary, Shandong Taibang, is currently the only plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province with a population of 93 million. The company is engaged primarily in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China.

Web site: http://www.ctbb.com.cn/

Last updated March 17, 2008